Performance Assessment of Binary Output Examinations in Medical Laboratories

Tu, 31.3.2026 | Original article from: Eurachem
Learn how to assess clinical test performance using sensitivity, specificity, and confidence intervals, and how to define fitness-for-purpose criteria for reliable diagnostic decisions.
<p>Eurachem: Performance Assessment of Binary Output Examinations in Medical Laboratories</p>

Eurachem: Performance Assessment of Binary Output Examinations in Medical Laboratories

1 - What is fitness for purpose? 

The test meets the necessary performance criteria for a clinical binary examination to ensure it is suitable for making accurate and reliable clinical decisions in the intended patient population. Among others, performance criteria include clinical sensitivity and clinical specificity. 

2 - How to assess clinical performance? 

Assessing the clinical performance of a binary examination, stating results as 'positive' or 'negative,' involves calculating the examination's Clinical Sensitivity and Clinical Specificity. From the physician's point of view, clinical performance is evaluated by using predictive values, i.e., how likely is it that a positive or negative result corresponds to the presence or absence of the condition, which is also influenced by the prevalence of the condition in the population being tested. 

3 - What is Clinical Sensitivity? 

Clinical sensitivity (SS), also known as the True Positive Rate, measures the proportion of true positives correctly identified by the test. Data from a group of subjects who have been confirmed to have the disease or condition through diagnosis or a gold standard test (D1 in Table 1) are needed to calculate clinical sensitivity.

Eurachem: Table 1. 2x2 Contingency table for clinical diagnosis.Eurachem: Table 1. 2x2 Contingency table for clinical diagnosis.

The formula for clinical sensitivity is: 

SS = tp / (tp + fn), with: 

  • tp, True Positives are the cases where the test correctly identifies the presence of the disease. 
  • fn, False Negatives are the cases where the test incorrectly identifies the absence of the disease when it is actually present. 

Table 1 represents the components of clinical sensitivity and specificity. Figure 1 illustrates an example of the overlapping of the number of components. The symbol "∩" represents the intersection of groups. For example, D1∩n denotes the set of negative results obtained for known positive cases, i.e., false negatives.

4 - What is Clinical Specificity? 

Clinical Specificity (SP), also known as the True Negative Rate, measures the proportion of true negatives correctly identified by the test. Data from a group of subjects who have been confirmed not to have the disease or condition through a gold standard test (D0 in Table 1) are needed to calculate clinical specificity.

The formula for clinical specificity is: 

SP = tn / (tn + fp), where: 

  • tn, True Negatives are the cases where the test correctly identifies the absence of the disease. 
  • fp, False Positives are the cases where the test incorrectly identifies the presence of the disease when it is actually absent. 

Eurachem: Figure 1. Graphical representation of an example of tp (D1∩p), tn (D0∩n), fn (D1∩n), and fp (D0∩p).Eurachem: Figure 1. Graphical representation of an example of tp (D1∩p), tn (D0∩n), fn (D1∩n), and fp (D0∩p).

5 - How to calculate the uncertainty of clinical sensitivity and specificity?

Calculating clinical sensitivity and specificity uncertainty involves statistical methods that estimate each parameter's confidence interval (CI). These intervals provide a range of values within which the true sensitivity or specificity is expected to lie with a certain level of confidence, typically 95 %. Please refer to the AQA:2021 for information about statistical models to compute the 95 % CI [1].

6 - How to define targets? 

Target minimum values for clinical sensitivity and specificity should be identified. These values may originate from regulations or criteria based on the intended use of the binary results. A target or minimum value for the lower limit of the 95 % CI for result rate, i.e., SS or SP, (LLSS.95 or LLSP.95) or the upper limit of the 95 % CI for result rate (HLSS.95 or HLSS.95) should also be defined according to the purpose of the analysis. The target or minimum value (LLSStg or LLSPtg) is particularly significant when the impact of false results is critical. For example, for blood components used in transfusions, the screening for infectious diseases should be performed with tests associated with an LLSS.95 close to 100 %. 

Figure 2 illustrates five different tests, each assessed for clinical sensitivity and its associated uncertainty. These cases reflect different levels of compliance with a target sensitivity of 0.5. Case 1 is non-compliant, Cases 2 to 4 are partially compliant, and Case 5 is compliant. From a simplified statistical power view, the laboratory should always take into account the minimum number of samples when defining its target. This number can be estimated by simulation. For example, for a clinical sensitivity of 90 % the evaluation will require a minimum of 10 samples. It should be emphasized that samples must be representative of the target population for a clinical power evaluation - for example, epidemiologically representative samples of the types and subtypes of a given virological agent are required.

Eurachem: Figure 2. Compliance assessment with clinical sensitivity uncertainty using the lower 95% confidence interval limit for five performance assessment scenarios.Eurachem: Figure 2. Compliance assessment with clinical sensitivity uncertainty using the lower 95% confidence interval limit for five performance assessment scenarios.

Resources

[1] R. Bettencourt da Silva and S. L. R. Ellison (eds.) Eurachem/CITAC Guide: Assessment of performance and uncertainty in qualitative chemical analysis. (1st ed. 2021). 

Eurachem
LinkedIn Logo
 

Related articles

Cumulative Neutral Loss Model for Fragment Deconvolution in Electrospray Ionization High-Resolution Mass Spectrometry Data
Article | Scientific article

Cumulative Neutral Loss Model for Fragment Deconvolution in Electrospray Ionization High-Resolution Mass Spectrometry Data

In the article published in ACS Analytical Chemistry the researchers presented a new algorithm for improving spectral cleanup in nontarget analysis.
Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum
Scientific article | Science and research

Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum

This pilot study shows lipidomic profiling by UHPSFC–MS can detect pancreatic cancer from blood samples with >95% accuracy and higher sensitivity than CA 19-9.
On-Site Microfluidic Assay for the Detection of Multiple Drugs in Urine
Scientific article | Science and research

On-Site Microfluidic Assay for the Detection of Multiple Drugs in Urine

This study presents a fluorescence-based microfluidic assay for rapid, simultaneous detection of multiple drugs in urine with high sensitivity and specificity.
Use of uncertainty in compliance
Article | Academy

Use of uncertainty in compliance

In this leaflet we present the Eurachem/CITAC guide on how to assess compliance with a specification or a regulation.
 

Related articles

Cumulative Neutral Loss Model for Fragment Deconvolution in Electrospray Ionization High-Resolution Mass Spectrometry Data
Article | Scientific article

Cumulative Neutral Loss Model for Fragment Deconvolution in Electrospray Ionization High-Resolution Mass Spectrometry Data

In the article published in ACS Analytical Chemistry the researchers presented a new algorithm for improving spectral cleanup in nontarget analysis.
Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum
Scientific article | Science and research

Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum

This pilot study shows lipidomic profiling by UHPSFC–MS can detect pancreatic cancer from blood samples with >95% accuracy and higher sensitivity than CA 19-9.
On-Site Microfluidic Assay for the Detection of Multiple Drugs in Urine
Scientific article | Science and research

On-Site Microfluidic Assay for the Detection of Multiple Drugs in Urine

This study presents a fluorescence-based microfluidic assay for rapid, simultaneous detection of multiple drugs in urine with high sensitivity and specificity.
Use of uncertainty in compliance
Article | Academy

Use of uncertainty in compliance

In this leaflet we present the Eurachem/CITAC guide on how to assess compliance with a specification or a regulation.
 

Related articles

Cumulative Neutral Loss Model for Fragment Deconvolution in Electrospray Ionization High-Resolution Mass Spectrometry Data
Article | Scientific article

Cumulative Neutral Loss Model for Fragment Deconvolution in Electrospray Ionization High-Resolution Mass Spectrometry Data

In the article published in ACS Analytical Chemistry the researchers presented a new algorithm for improving spectral cleanup in nontarget analysis.
Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum
Scientific article | Science and research

Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum

This pilot study shows lipidomic profiling by UHPSFC–MS can detect pancreatic cancer from blood samples with >95% accuracy and higher sensitivity than CA 19-9.
On-Site Microfluidic Assay for the Detection of Multiple Drugs in Urine
Scientific article | Science and research

On-Site Microfluidic Assay for the Detection of Multiple Drugs in Urine

This study presents a fluorescence-based microfluidic assay for rapid, simultaneous detection of multiple drugs in urine with high sensitivity and specificity.
Use of uncertainty in compliance
Article | Academy

Use of uncertainty in compliance

In this leaflet we present the Eurachem/CITAC guide on how to assess compliance with a specification or a regulation.
 

Related articles

Cumulative Neutral Loss Model for Fragment Deconvolution in Electrospray Ionization High-Resolution Mass Spectrometry Data
Article | Scientific article

Cumulative Neutral Loss Model for Fragment Deconvolution in Electrospray Ionization High-Resolution Mass Spectrometry Data

In the article published in ACS Analytical Chemistry the researchers presented a new algorithm for improving spectral cleanup in nontarget analysis.
Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum
Scientific article | Science and research

Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum

This pilot study shows lipidomic profiling by UHPSFC–MS can detect pancreatic cancer from blood samples with >95% accuracy and higher sensitivity than CA 19-9.
On-Site Microfluidic Assay for the Detection of Multiple Drugs in Urine
Scientific article | Science and research

On-Site Microfluidic Assay for the Detection of Multiple Drugs in Urine

This study presents a fluorescence-based microfluidic assay for rapid, simultaneous detection of multiple drugs in urine with high sensitivity and specificity.
Use of uncertainty in compliance
Article | Academy

Use of uncertainty in compliance

In this leaflet we present the Eurachem/CITAC guide on how to assess compliance with a specification or a regulation.